Biotechnology The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s Tykerb and Herceptin (trastuzumab) in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival (DFS), says an analyst with research and consulting firm GlobalData. 16 June 2014